STOCK TITAN

[S-8 POS] Verve Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Verve Therapeutics, Inc. ("Verve") filed Post-Effective Amendment No. 1 to five previously effective Form S-8 registration statements that in aggregate covered approximately 31.2 million shares of common stock reserved for the company’s 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, Amended & Restated 2021 Employee Stock Purchase Plan, and 2024 Inducement Stock Incentive Plan.

On 25 July 2025, Verve completed its merger with Eli Lilly and Company through Ridgeway Acquisition Corporation and is now an indirect, wholly-owned Lilly subsidiary. Because Verve will no longer issue shares to the public, it has terminated all offerings under the S-8s and is deregistering any unsold shares that remained available under the equity plans. After effectiveness of these amendments, no Verve securities remain registered with the SEC pursuant to the referenced S-8 filings.

The document is purely administrative: it does not introduce new financing, earnings data, or changes to plan terms. It simply formalises the cleanup of outstanding share registrations following the closing of the Lilly transaction.

Verve Therapeutics, Inc. ("Verve") ha presentato l'Emendamento Post-Efficacia n. 1 a cinque dichiarazioni di registrazione Form S-8 precedentemente efficaci, che complessivamente coprivano circa 31,2 milioni di azioni ordinarie riservate per il Piano di Incentivi Azionari 2018, il Piano di Incentivi Azionari 2021, il Piano di Acquisto Azionario per Dipendenti 2021 Modificato e Ristabilito e il Piano di Incentivi Azionari di Induzione 2024.

Il 25 luglio 2025, Verve ha completato la fusione con Eli Lilly and Company tramite Ridgeway Acquisition Corporation ed è ora una controllata indiretta interamente posseduta da Lilly. Poiché Verve non emetterà più azioni al pubblico, ha terminato tutte le offerte ai sensi dei moduli S-8 ed è in procinto di cancellare la registrazione delle azioni invendute ancora disponibili nei piani azionari. Dopo l'efficacia di questi emendamenti, non risultano più titoli Verve registrati presso la SEC in base ai moduli S-8 indicati.

Il documento è di natura puramente amministrativa: non introduce nuovi finanziamenti, dati sugli utili o modifiche ai termini dei piani. Semplicemente formalizza la pulizia delle registrazioni azionarie residue a seguito della chiusura dell'operazione con Lilly.

Verve Therapeutics, Inc. ("Verve") presentó la Enmienda Post-Efectiva N.º 1 a cinco declaraciones de registro Formulario S-8 previamente vigentes, que en conjunto cubrían aproximadamente 31,2 millones de acciones ordinarias reservadas para el Plan de Incentivos de Acciones 2018, el Plan de Incentivos de Acciones 2021, el Plan Modificado y Reestablecido de Compra de Acciones para Empleados 2021 y el Plan de Incentivos de Acciones por Inducción 2024.

El 25 de julio de 2025, Verve completó su fusión con Eli Lilly and Company a través de Ridgeway Acquisition Corporation y ahora es una subsidiaria indirecta de propiedad total de Lilly. Dado que Verve ya no emitirá acciones al público, ha terminado todas las ofertas bajo los formularios S-8 y está dado de baja cualquier acción no vendida que quedaba disponible bajo los planes accionarios. Tras la efectividad de estas enmiendas, no quedan valores de Verve registrados en la SEC conforme a los formularios S-8 mencionados.

El documento es puramente administrativo: no introduce nuevos financiamientos, datos de ganancias ni cambios en los términos de los planes. Simplemente formaliza la limpieza de las registraciones de acciones pendientes tras el cierre de la transacción con Lilly.

Verve Therapeutics, Inc.("Verve")는 이전에 효력이 있었던 다섯 건의 Form S-8 등록서류에 대한 사후효력 수정서 1호를 제출했으며, 이 서류들은 총 약 3,120만 주의 보통주를 회사의 2018년 주식 인센티브 플랜, 2021년 주식 인센티브 플랜, 개정 및 재정비된 2021년 직원 주식 구매 플랜, 2024년 유인 주식 인센티브 플랜에 예약해 두었습니다.

2025년 7월 25일, Verve는 Ridgeway Acquisition Corporation을 통해 Eli Lilly and Company와 합병을 완료했으며 현재는 Lilly의 간접 완전 자회사입니다. Verve가 더 이상 대중에게 주식을 발행하지 않기 때문에, S-8에 따른 모든 공모를 종료하고 주식 플랜에 따라 남아 있던 미판매 주식의 등록을 말소하고 있습니다. 이 수정서가 효력을 발생한 후에는, 참조된 S-8 등록에 따라 Verve 증권이 SEC에 더 이상 등록되어 있지 않습니다.

이 문서는 순전히 행정적인 것으로, 새로운 자금 조달, 수익 데이터, 또는 플랜 조건 변경을 포함하지 않습니다. 단지 Lilly 거래 종료 후 남아있던 주식 등록을 정리하는 절차를 공식화한 것입니다.

Verve Therapeutics, Inc. (« Verve ») a déposé l’Amendement Post-Efficace n° 1 à cinq déclarations d’enregistrement Formulaire S-8 précédemment en vigueur, couvrant au total environ 31,2 millions d’actions ordinaires réservées pour le Plan d’Incitations en Actions 2018, le Plan d’Incitations en Actions 2021, le Plan Modifié et Révisé d’Achat d’Actions Employés 2021, et le Plan d’Incitations en Actions d’Induction 2024.

Le 25 juillet 2025, Verve a finalisé sa fusion avec Eli Lilly and Company via Ridgeway Acquisition Corporation et est désormais une filiale indirecte en propriété exclusive de Lilly. Comme Verve ne délivrera plus d’actions au public, elle a mis fin à toutes les offres sous les formulaires S-8 et procède à la radiation des actions invendues encore disponibles dans le cadre des plans d’actions. Après l’entrée en vigueur de ces amendements, aucun titre Verve n’est plus enregistré auprès de la SEC conformément aux formulaires S-8 mentionnés.

Ce document est purement administratif : il n’introduit aucun nouveau financement, données de résultats ou modification des termes des plans. Il formalise simplement le nettoyage des enregistrements d’actions en suspens suite à la clôture de la transaction avec Lilly.

Verve Therapeutics, Inc. („Verve“) hat die Nachwirkungsänderung Nr. 1 zu fünf zuvor wirksamen Form S-8-Registrierungserklärungen eingereicht, die zusammen etwa 31,2 Millionen Stammaktien abdeckten, die für den Aktienanreizplan 2018, den Aktienanreizplan 2021, den geänderten und neu gefassten Mitarbeiteraktienkaufplan 2021 sowie den Aktienanreizplan 2024 reserviert waren.

Am 25. Juli 2025 hat Verve die Fusion mit Eli Lilly and Company über Ridgeway Acquisition Corporation abgeschlossen und ist nun eine indirekte, hundertprozentige Tochtergesellschaft von Lilly. Da Verve keine Aktien mehr öffentlich ausgeben wird, hat das Unternehmen alle Angebote unter den S-8-Formularen beendet und meldet alle unverkäuflichen Aktien, die noch unter den Aktienplänen verfügbar waren, ab. Nach Wirksamwerden dieser Änderungen sind keine Verve-Wertpapiere mehr bei der SEC unter den genannten S-8-Anmeldungen registriert.

Das Dokument ist rein administrativ: Es führt keine neuen Finanzierungen, Gewinnzahlen oder Änderungen der Planbedingungen ein. Es formalisierte lediglich die Bereinigung der ausstehenden Aktienregistrierungen nach Abschluss der Lilly-Transaktion.

Positive
  • Merger completion with Eli Lilly confirmed, eliminating the need for separate Verve share registrations and potential equity overhang.
Negative
  • None.

Insights

TL;DR: Procedural filing removes 31 M unsold S-8 shares after Lilly acquisition; no financial impact.

The post-effective amendments are standard practice once a target is folded into a parent company. All equity incentive and purchase plan shares that were previously registered but not issued are now withdrawn, eliminating any potential share overhang. No new securities are being offered, so dilution risk is moot. Because the merger closed on 25 July 2025, investors have already priced in the corporate action. Impact to remaining stakeholders (now Lilly) is negligible; the action simply tidies the SEC register.

TL;DR: Filing fulfills Rule 478 obligations; confirms Verve’s transition to private status inside Lilly.

Deregistering unsold S-8 shares demonstrates compliance with undertakings in each registration statement and avoids unnecessary reporting obligations. It signals that Verve’s standalone equity compensation programs will either be rolled into Lilly plans or settled in parent shares going forward. Corporate governance risk is minimal because the parent now controls all voting power; minority public shareholders no longer exist. The filing is therefore largely housekeeping, with no material governance or capital-structure consequences.

Verve Therapeutics, Inc. ("Verve") ha presentato l'Emendamento Post-Efficacia n. 1 a cinque dichiarazioni di registrazione Form S-8 precedentemente efficaci, che complessivamente coprivano circa 31,2 milioni di azioni ordinarie riservate per il Piano di Incentivi Azionari 2018, il Piano di Incentivi Azionari 2021, il Piano di Acquisto Azionario per Dipendenti 2021 Modificato e Ristabilito e il Piano di Incentivi Azionari di Induzione 2024.

Il 25 luglio 2025, Verve ha completato la fusione con Eli Lilly and Company tramite Ridgeway Acquisition Corporation ed è ora una controllata indiretta interamente posseduta da Lilly. Poiché Verve non emetterà più azioni al pubblico, ha terminato tutte le offerte ai sensi dei moduli S-8 ed è in procinto di cancellare la registrazione delle azioni invendute ancora disponibili nei piani azionari. Dopo l'efficacia di questi emendamenti, non risultano più titoli Verve registrati presso la SEC in base ai moduli S-8 indicati.

Il documento è di natura puramente amministrativa: non introduce nuovi finanziamenti, dati sugli utili o modifiche ai termini dei piani. Semplicemente formalizza la pulizia delle registrazioni azionarie residue a seguito della chiusura dell'operazione con Lilly.

Verve Therapeutics, Inc. ("Verve") presentó la Enmienda Post-Efectiva N.º 1 a cinco declaraciones de registro Formulario S-8 previamente vigentes, que en conjunto cubrían aproximadamente 31,2 millones de acciones ordinarias reservadas para el Plan de Incentivos de Acciones 2018, el Plan de Incentivos de Acciones 2021, el Plan Modificado y Reestablecido de Compra de Acciones para Empleados 2021 y el Plan de Incentivos de Acciones por Inducción 2024.

El 25 de julio de 2025, Verve completó su fusión con Eli Lilly and Company a través de Ridgeway Acquisition Corporation y ahora es una subsidiaria indirecta de propiedad total de Lilly. Dado que Verve ya no emitirá acciones al público, ha terminado todas las ofertas bajo los formularios S-8 y está dado de baja cualquier acción no vendida que quedaba disponible bajo los planes accionarios. Tras la efectividad de estas enmiendas, no quedan valores de Verve registrados en la SEC conforme a los formularios S-8 mencionados.

El documento es puramente administrativo: no introduce nuevos financiamientos, datos de ganancias ni cambios en los términos de los planes. Simplemente formaliza la limpieza de las registraciones de acciones pendientes tras el cierre de la transacción con Lilly.

Verve Therapeutics, Inc.("Verve")는 이전에 효력이 있었던 다섯 건의 Form S-8 등록서류에 대한 사후효력 수정서 1호를 제출했으며, 이 서류들은 총 약 3,120만 주의 보통주를 회사의 2018년 주식 인센티브 플랜, 2021년 주식 인센티브 플랜, 개정 및 재정비된 2021년 직원 주식 구매 플랜, 2024년 유인 주식 인센티브 플랜에 예약해 두었습니다.

2025년 7월 25일, Verve는 Ridgeway Acquisition Corporation을 통해 Eli Lilly and Company와 합병을 완료했으며 현재는 Lilly의 간접 완전 자회사입니다. Verve가 더 이상 대중에게 주식을 발행하지 않기 때문에, S-8에 따른 모든 공모를 종료하고 주식 플랜에 따라 남아 있던 미판매 주식의 등록을 말소하고 있습니다. 이 수정서가 효력을 발생한 후에는, 참조된 S-8 등록에 따라 Verve 증권이 SEC에 더 이상 등록되어 있지 않습니다.

이 문서는 순전히 행정적인 것으로, 새로운 자금 조달, 수익 데이터, 또는 플랜 조건 변경을 포함하지 않습니다. 단지 Lilly 거래 종료 후 남아있던 주식 등록을 정리하는 절차를 공식화한 것입니다.

Verve Therapeutics, Inc. (« Verve ») a déposé l’Amendement Post-Efficace n° 1 à cinq déclarations d’enregistrement Formulaire S-8 précédemment en vigueur, couvrant au total environ 31,2 millions d’actions ordinaires réservées pour le Plan d’Incitations en Actions 2018, le Plan d’Incitations en Actions 2021, le Plan Modifié et Révisé d’Achat d’Actions Employés 2021, et le Plan d’Incitations en Actions d’Induction 2024.

Le 25 juillet 2025, Verve a finalisé sa fusion avec Eli Lilly and Company via Ridgeway Acquisition Corporation et est désormais une filiale indirecte en propriété exclusive de Lilly. Comme Verve ne délivrera plus d’actions au public, elle a mis fin à toutes les offres sous les formulaires S-8 et procède à la radiation des actions invendues encore disponibles dans le cadre des plans d’actions. Après l’entrée en vigueur de ces amendements, aucun titre Verve n’est plus enregistré auprès de la SEC conformément aux formulaires S-8 mentionnés.

Ce document est purement administratif : il n’introduit aucun nouveau financement, données de résultats ou modification des termes des plans. Il formalise simplement le nettoyage des enregistrements d’actions en suspens suite à la clôture de la transaction avec Lilly.

Verve Therapeutics, Inc. („Verve“) hat die Nachwirkungsänderung Nr. 1 zu fünf zuvor wirksamen Form S-8-Registrierungserklärungen eingereicht, die zusammen etwa 31,2 Millionen Stammaktien abdeckten, die für den Aktienanreizplan 2018, den Aktienanreizplan 2021, den geänderten und neu gefassten Mitarbeiteraktienkaufplan 2021 sowie den Aktienanreizplan 2024 reserviert waren.

Am 25. Juli 2025 hat Verve die Fusion mit Eli Lilly and Company über Ridgeway Acquisition Corporation abgeschlossen und ist nun eine indirekte, hundertprozentige Tochtergesellschaft von Lilly. Da Verve keine Aktien mehr öffentlich ausgeben wird, hat das Unternehmen alle Angebote unter den S-8-Formularen beendet und meldet alle unverkäuflichen Aktien, die noch unter den Aktienplänen verfügbar waren, ab. Nach Wirksamwerden dieser Änderungen sind keine Verve-Wertpapiere mehr bei der SEC unter den genannten S-8-Anmeldungen registriert.

Das Dokument ist rein administrativ: Es führt keine neuen Finanzierungen, Gewinnzahlen oder Änderungen der Planbedingungen ein. Es formalisierte lediglich die Bereinigung der ausstehenden Aktienregistrierungen nach Abschluss der Lilly-Transaktion.

As filed with the Securities and Exchange Commission on July 25, 2025

Registration No. 333-257175

Registration No. 333-263518

Registration No. 333-270207

Registration No. 333-277385

Registration No. 333-285309

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-257175

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263518

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270207

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277385

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285309

UNDER

THE SECURITIES ACT OF 1933

 

 

VERVE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   82-4800132
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

201 Brookline Avenue, Suite 601

Boston, Massachusetts

  02215
(Address of Principal Executive Offices)   (Zip Code)

2018 Equity Incentive Plan

2021 Stock Incentive Plan

Amended and Restated 2021 Employee Stock Purchase Plan

2024 Inducement Stock Incentive Plan

(Full titles of the plans)

Jonathan R. Haug

President

Verve Therapeutics, Inc.

Lilly Corporate Center

Indianapolis, Indiana 46285

(Name and address of agent for service)

(317) 276-2000

(Telephone number, including area code, of agent for service)

 

 

Copy to:

Sophia Hudson, P.C.

Sharon Freiman, P.C.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, New York 10022

Telephone: (212) 446-4800

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (these “Post-Effective Amendments”) filed by Verve Therapeutics, Inc. (the “Registrant”) relate to the following registration statements on Form S-8 (together, the “Registration Statements”):

 

1.

Registration Statement No.  333-257175, registering an aggregate of 10,321,696 shares of the Registrant’s common stock, $0.001 par value per share (the “Common Stock”), consisting of (i) 5,258,661 shares of Common Stock issuable under the Registrant’s 2018 Equity Incentive Plan, (ii) 4,629,719 shares of Common Stock issuable under the Registrant’s 2021 Stock Incentive Plan (the “2021 Plan”) and (iii) 433,316 shares of Common Stock issuable under the Registrant’s Amended and Restated 2021 Employee Stock Purchase Plan (the “ESPP”), which was filed with the U.S. Securities and Exchange Commission (the “Commission”) on June 17, 2021;

 

2.

Registration Statement No.  333-263518, registering an aggregate of 2,910,704 shares of Common Stock consisting of (i) 2,425,587 shares of Common Stock issuable under the 2021 Plan and (ii) 485,117 shares of Common Stock issuable under the ESPP, which was filed with the Commission on March 14, 2022;

 

3.

Registration Statement No.  333-270207, registering an aggregate of 3,703,849 shares of Common Stock consisting of (i) 3,086,541 shares of Common Stock issuable under the 2021 Plan and (ii) 617,308 shares of Common Stock issuable under the ESPP, which was filed with the Commission on March 2, 2023;

 

4.

Registration Statement No.  333-277385, registering an aggregate of 8,918,182 shares of Common Stock consisting of (i) 4,098,485 shares of Common Stock issuable under the 2021 Plan, (ii) 819,697 shares of Common Stock issuable under the ESPP and (iii) 4,000,000 shares of Common Stock issuable under the Registrant’s 2024 Inducement Stock Incentive Plan, which was filed with the Commission on February 27, 2024; and

 

5.

Registration Statement No.  333-285309, registering an aggregate of 5,325,493 shares of Common Stock consisting of (i) 4,437,911 shares of Common Stock issuable under the 2021 Plan and (ii) 887,582 shares of Common Stock issuable under the ESPP, which was filed with the Commission on February 27, 2025.

On July 25, 2025, pursuant to the Agreement and Plan of Merger, dated June 16, 2025 (the “Merger Agreement”), by and among the Registrant, Eli Lilly and Company (“Parent”) and Ridgeway Acquisition Corporation (“Purchaser”), Purchaser merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and becoming an indirect wholly-owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under such Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of the Registration Statements and removes from registration all of the securities that remain unsold under the Registration Statements as of the date hereof, if any.

The Registrant is filing these Post-Effective Amendments to withdraw and remove from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Registrant pursuant to the Registration Statements.


SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Indianapolis, Indiana, on July 25, 2025.

 

VERVE THERAPEUTICS, INC.
By:   /s/ Jonathan R. Haug
Name:   Jonathan R. Haug
Title:   President

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments.

FAQ

Why did Verve Therapeutics (VERV) file these Post-Effective Amendments?

To deregister all unsold shares previously registered on five Form S-8s following its merger with Eli Lilly.

How many Verve shares are being deregistered?

Up to 31.2 million shares covering four equity compensation plans are withdrawn.

Does the filing affect Verve’s public shareholders?

No; Verve is now a wholly-owned Lilly subsidiary, so no public float remains.

Are any new financial results or earnings disclosed?

No. The amendment is administrative and contains no operating or financial data.

What happens to Verve’s equity incentive plans after deregistration?

They can no longer issue Verve common stock; future awards would need to use Lilly equity or cash.
Verve Therapeutics, Inc.

NASDAQ:VERV

VERV Rankings

VERV Latest News

VERV Latest SEC Filings

VERV Stock Data

991.37M
84.54M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON